C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-06

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine changes in plasma C15:0 levels in young adults with BMI ≥ 25 in response to 12 weeks of daily oral C15:0 supplementation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males

NCT03342599

Metabolic Syndrome Obesity

COMPLETED NA

The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health

NCT03716791

Obesity

COMPLETED NA

A Pharmacokinetic Study of a Novel Nutritional Product on Healthy Men and Women

NCT06316700

Healthy Aging

COMPLETED NA

Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes

NCT06376695

Abdominal Pain GI Disorders Digestion

COMPLETED NA

The Effects of a Novel Nutritional Product on Nutrient Status and Digestive Health

NCT06181214

Gastrointestinal Microbiome Nutrition, Healthy Healthy Aging

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Metabolic syndrome is a disturbance in how the body processes both carbohydrates and fats. This condition has become common in children and young adults, especially in association with excess body fat. People with metabolic syndrome are at increased risk for type 2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD). Diet is believed to play an important role in both developing and treating metabolic syndrome. Studies have shown that low dietary intake of a type of fats known as odd chain fatty acids is associated with a higher risk for each of the metabolic syndrome associated conditions of diabetes, heart disease, and liver disease. Supplementation with one specific odd chain fatty acid known as C15:0 has shown to decrease the effects of metabolic syndrome in both cellular and animal models. In people, the epidemiology of consumption of C15:0 in the diet is consistent with this belief. However, clinical trials have yet to be done with supplemental C15:0. This study is a pilot study of C15:0 supplementation in a group of young adults at risk for metabolic syndrome. The study will determine how well supplementation with C15:0 daily for 12 weeks is able to raise levels of C15:0 in the blood when compared to placebo. The study will also look for signs that increasing blood levels of C15:0 leads to changes in physiology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

200mg of pentadecanoic acid (C15:0) supplementation in capsules form

Group Type ACTIVE_COMPARATOR

Supplement

Intervention Type DIETARY_SUPPLEMENT

200mg C15:0 once daily

Placebo

Matching placebo in capsules form

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Matching placebo once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supplement

200mg C15:0 once daily

Intervention Type DIETARY_SUPPLEMENT

Placebo

Matching placebo once daily

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 through 25 years
* Body Mass Index ≥ 25 Kg/m2

Exclusion Criteria

* Reported habitual dietary intake of C15:0 that consistently exceeds 250 mg per day
* Significant alcohol consumption (average consumption \>1 drink/day for females, \>2 drink/day for males or episodes of binge drinking \>5 drinks/day)
* Inability to swallow capsules
* Type 1 or Type 2 Diabetes
* Liver Cirrhosis
* Pregnancy
* Body weight greater than 125 kg at screening
* LDL-cholesterol \> 160 mg/dL
* Triglycerides \> 500 mg/dL
* Hemoglobin \< 10.0 gm/dL
* Current Omega 3 Fatty Acid supplement usage
* Current use of Statin medications
* Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study
* Patients who are currently enrolled in a clinical trial or who received an investigational study drug within 180 days of screening.
* Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator.
* Failure to give informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No